Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Top Cited Papers
Open Access
- 22 March 2010
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 16 (9) , 1245-1256
- https://doi.org/10.1016/j.bbmt.2010.03.014
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P01 CA30206 and P50 CA107399)
- General Clinical Research Center (M01 RR0004)
This publication has 34 references indexed in Scilit:
- The promise and potential pitfalls of chimeric antigen receptorsCurrent Opinion in Immunology, 2009
- Immunomodulation in the treatment of haematological malignanciesClinical and Experimental Medicine, 2009
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's LymphomaAnnual Review of Medicine, 2008
- Engineering Antitumor Immunity by T-Cell Adoptive ImmunotherapyHematology-American Society Hematology Education Program, 2007
- Current status of immunotherapy in B cell malignancies.Current Drug Targets, 2006
- Genetic engineering of cytolytic T lymphocytes for adoptive T‐cell therapy of neuroblastomaThe Journal of Gene Medicine, 2004
- Immunotherapy for LymphomasInternational Journal of Hematology, 2003
- T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B–lineage leukemia effectBlood, 2003
- Human T Lymphocyte Genetic Modification with Naked DNAMolecular Therapy, 2000
- CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.Transplantation and Cellular Therapy, 1998